Putting big pharma in charge of global vaccine rollout was a big mistake Tue 8 Feb 2022 12.13 EST Last modified on Tue 8 Feb 2022 19.30 EST
Pfizer has had an exceptionally good pandemic. Today it announced that its Covid-19 vaccine brought in $37bn billion last year, making it easily the most lucrative medicine in any given year in history.
That isn’t all. For a company that was until recently the least trusted company in the least trusted industrial sector in the United States, Covid-19 has been a PR coup. Pfizer has become a household name over the last 12 months. The company was toasted on nights out in Tel Aviv, and there are cocktails named after its vaccine in bars across the world. The US president referred to Pfizer’s chief executive, Albert Bourla, as a “good friend”, and the great man parked his jet next to Boris Johnson’s at last year’s G7 summit in Cornwall.
The global vaccine rollout has created levels of inequality so great that many call it a ‘vaccine apartheid’. Pharmaceutical corporations like Pfizer have led this rollout, setting the terms by which they sell vaccines and deciding who to prioritise. Ultimately, their approach affects who does, and does not, receive vaccines. https://www.theguardian.com/commentisfree/2022/feb/08/big-pharma-global-vaccine-rollout-covid-pfizer
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.